Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study.

Date publication

août 2025

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine

Tous les auteurs :
Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, Amiot A, Vuitton L, Treton X, Caillo L, Pereira B, Fumery M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40835043

Résumé

We compared the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis (UC) previously exposed to at least one anti-TNF agent.

Mots clés

JAK inhibitors, Ulcerative colitis, inflammatory bowel disease, tofacitinib, ustekinumab

Référence

Clin Gastroenterol Hepatol. 2025 08 18;: